Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Advanced Solid Tumors 8Mesothelioma, Malignant 6Mesothelioma 6Advanced Solid Tumours 3Urinary Bladder Neoplasms 2Solid Tumor 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Part A and B: Advanced Solid Malignancies 1Ovarian Neoplasms 1Locally Advanced or Metastatic Solid Tumours 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck 1Advanced Solid Tumor 1Adenocarcinoma Of Esophagus 1

Interventions

tremelimumab 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Part A and B: Advanced Solid Malignancies × durvalumab × Other solid neoplasm × Clear all
NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

AstraZeneca

Phase 1 Completed
65 enrolled
Other solid neoplasmThoracic

Part A and B: Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡